The dramatic rise in autism diagnoses worldwide forces an uncomfortable question: are we getting better at identifying a genuinely common condition, or have shifting diagnostic thresholds begun capturing individuals who would not meaningfully benefit from the label? This tension sits at the heart of a critical analysis published in Cadernos de Saúde Pública, and its implications extend well beyond Brazil's borders.
The analysis centers on the concept of hyperdiagnosis — defined here not as misdiagnosis, but as identification of autism spectrum disorder (ASD) in cases where functional impairment is minimal or absent. Brazilian prevalence data now sit at approximately 1.2% of the population, mirroring a global upward trend documented across recent epidemiological literature. The authors attribute this acceleration to several converging forces: successive revisions to diagnostic criteria that folded milder, more heterogeneous presentations into the ASD umbrella, heightened societal awareness, institutional pressures for behavioral conformity in school settings, and, notably, instrumental use of diagnoses to access educational and social benefits. The analysis draws a deliberate distinction between early and judicious diagnosis — clinically warranted and functionally meaningful — and evaluations deemed hasty or superficial.
The debate this paper enters is long-running and unresolved. The DSM-5's consolidation of prior subtypes (including Asperger's syndrome) into a single spectrum was epidemiologically consequential, and critics have argued since 2013 that broadening categorical boundaries inevitably inflates prevalence estimates without proportionally improving outcomes. What makes this analysis particularly relevant is its attention to downstream harms often underweighted in public discourse: early stigmatization of children who may not require intensive intervention, misallocation of scarce therapeutic resources, emotional burden on families navigating a system with incentive structures that may reward diagnosis over watchful clinical judgment, and distorted epidemiological signals that compromise policy planning. As a commentary rather than primary data study, the piece offers no new prevalence estimates, but its synthesis of structural and clinical drivers provides a useful framework for clinicians and policymakers alike. The core challenge it identifies — distinguishing genuine prevalence growth from diagnostic artifact — remains one of the more difficult methodological problems in developmental psychiatry.